This Biotech Startup Just Raised $46M to Tackle a Rare Kidney Disease

Jan de Vries · 2026-08-07

### A Big Win for Rare Disease Research A Glasgow-based biopharmaceutical company just closed a significant funding round, and it could change the game for millions of people living with a rare genetic kidney condition. Mironid has secured $46 million (€39.9 million) in a Series B financing round to push its lead drug candidate through clinical development. That's not pocket change. The round was led by the Scottish National Investment Bank, with support from a solid group of existing backers including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When you see that kind of syndicate come together, it sends a clear signal about the potential here. ### What Is ADPKD, and Why Should You Care? Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary kidney disorder out there. It affects more than 12 million people worldwide, and here's the sobering part: about 50% of patients develop kidney failure by age 60. That's a brutal statistic. Neil Wilkie, CEO of Mironid, put it plainly: "Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD." He added that the financing will help the company "progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases." ### The Science Behind the Hope Mironid was spun out of the University of Strathclyde and Heriot-Watt University back in 2015. It's built on over three decades of research into PDE biology by Professor Miles Houslay. The company is headquartered in Glasgow and focuses on developing drug candidates for degenerative and rare genetic kidney diseases, along with major inflammatory diseases and cancer. The star of the show is Mironid's first-in-class LoAc small molecule candidate. Here's how it works: ADPKD is caused mostly by mutations in the PKD1 or PKD2 genes, which lead to uncontrolled growth of fluid-filled cysts in the kidneys. Over time, those cysts can crowd out healthy tissue and eventually cause kidney failure. Mironid's LoAc molecules directly target cyclic AMP (cAMP), a cellular signal that's active at every stage of the disease. cAMP drives both cell proliferation and fluid secretion within the cysts. By going after this pathway, the company's approach could prevent new cyst formation and stop existing cysts from growing. ### What the Preclinical Data Shows So far, the preclinical results look encouraging. The company reports significant efficacy and a favorable safety profile across disease endpoints, including reductions in cyst number and kidney volume. The argument is that this cAMP-modulating approach could offer a more durable treatment option with an improved side-effect profile compared with existing therapies. That's a big deal because current treatment options for ADPKD are limited. Patients often face years of managing symptoms, and for many, dialysis or a kidney transplant becomes inevitable. A therapy that could actually slow or halt disease progression would be transformative. ### Beyond ADPKD: A Broader Pipeline Mironid isn't just a one-trick pony. Beyond ADPKD, the pipeline targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways implicated in disease progression. The company operates on a research-and-development-led model, funded through venture capital and strategic investment, with the long-term goal of advancing its programs through preclinical and clinical trials toward commercialization. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed it up well: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." ### What's Next for Mironid The fresh capital follows an earlier Series A extension round, bringing the company's total funding since inception to roughly $47 million (€40.8 million). The new funds will go toward advancing the clinical development of the lead candidate, which means we could see meaningful trial results in the coming years. For anyone following the biotech space, this is one to watch. It's not every day you see a company with this kind of scientific pedigree, investor backing, and a genuinely novel approach to a disease that affects millions. If the clinical trials deliver on the promise of the preclinical data, Mironid could be well on its way to changing how ADPKD is treated.